WuXi XDC Earns Six Prestigious Awards at 2025 Extel Rankings for Leadership and Governance

WuXi XDC Achieves Remarkable Recognition at 2025 Extel Rankings

On May 19, 2025, WuXi XDC Cayman Inc. (stock code: 2268.HK), a prominent global Contract Research, Development, and Manufacturing Organization (CRDMO) focusing on the bioconjugate market, proudly announced its success in gaining multiple top honors at the 2025 Extel Rankings. These awards include 'Best CEO,' 'Best CFO,' 'Best Company Board,' 'Best IR Program,' 'Best IR Professional,' and 'Best ESG (Environmental, Social, and Governance)' awards, acknowledging WuXi XDC's excellence across varied categories.

This year marks the second consecutive win for WuXi XDC in the Extel rankings, reflecting the company's robust overall performance. It achieved a phenomenal 'Grand Slam' across all ranking categories and sectors encompassing 'All market capitalization,' 'Small and Medium-sized market capitalization,' and 'Chinese mainland.' The Extel rankings, previously known as those published by 'Institutional Investor,' are highly regarded in the financial community for rating companies based on votes from buy-side and sell-side professionals.

This year’s rankings attracted participation from 5,437 investment professionals representing 1,167 financial services firms. They voted on essential criteria such as senior executive accessibility, strategic execution, the empowerment of the investor relations (IR) team, timely disclosures, corporate governance, and ESG performance.

CFO Michael Xi shared, "It is an incredible honor for WuXi XDC to receive multiple awards at the Extel Award for two successive years. Such recognition signifies the global capital market's acknowledgment of our strategic positioning, governance practices, and commitment to value creation. We view these awards as both a recognition of our achievements and a responsibility toward our stakeholders. Moving forward, we aim to enhance our growth trajectory while ensuring sustainable shareholder returns through diligent market insights and operational efficiency in bioconjugate development."

WuXi XDC made its impressive debut on the Hong Kong Stock Exchange's Main Board in November 2023, raising over HKD 4 billion and earning the title of 'Best IPO' from IFR Asia in the same year. The firm was subsequently included in the Hong Kong Stock Connect list in March 2024. As of now, more than 30 sell-side analysts and firms cover WuXi XDC, and over 13% of the company's total issued shares are held within the Hong Kong Stock Connect framework.

Furthermore, WuXi XDC is included in several key indices, including the Hang Seng Composite Index (HSCI), Hang Seng Hong Kong Listed Biotechnology Index (HSHKBIO), Hang Seng Healthcare Index (HSHCI), Hang Seng Hong Kong US Biotechnology Index (HSUSB), and FTSE All-Cap, reflecting its esteemed position within the capital markets.

In recognition of its accomplishments, WuXi XDC has also received industry accolades such as 'Top Investor-Picked Companies,' 'Most Valuable Pharmaceutical and Healthcare Company,' and 'Top 20 Pharmaceutical Listed Companies in ESG Competitiveness 2024.'

In 2024, WuXi XDC solidified its leading role within the field of antibody-drug conjugates (ADCs) and made noteworthy strides in the bioconjugates CRDMO arena. The company experienced substantial revenue growth of 90.8% year-on-year, reaching RMB 4,052 million, while its net profit surged by an impressive 277.2% year-on-year to RMB 1,070 million. By the end of 2024, WuXi XDC had served nearly 500 clients worldwide and successfully delivered over 14,000 bioconjugate molecules as part of its 'Enable, Follow and Win the Molecule' strategy.

The total number of integrated CMC projects reached 194, effectively supporting 85 IND submissions. Furthermore, 13 of the top 20 global pharmaceutical companies have collaborated with WuXi XDC for research and development and manufacturing services on ADCs and extensive bioconjugates.

About WuXi XDC

WuXi XDC Cayman Inc. is a leading global CRDMO specializing in antibody-drug conjugates (ADCs) and broader bioconjugates. The company offers comprehensive contract research, development, and manufacturing services for bioconjugates, including antibody intermediates, chemical payloads and linkers, bioconjugate drug substances, and products. To learn more about WuXi XDC, please visit www.wuxixdc.com.

For Investors and Media Inquiries, please reach out via the provided contact information on their website.